• Species Reactivity
  Mouse
• Specificity
  Detects mouse IL‑6 R alphain ELISAs and Western blots. In sandwich ELISAs, less than 0.3% cross-reactivity with recombinant mouse (rm) IL‑6, recombinant human IL-6 R and rmgp130 is observed.
• Source
  Polyclonal Goat IgG
• Purification
  Antigen Affinity-purified
• Immunogen
  Mouse myeloma cell line NS0-derived recombinant mouse IL-6 R alpha
  Leu20-Glu357
  Accession # P22272
• Formulation
  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Endotoxin Level
  <0.10 eu="" per="" 1="" μg="" of="" the="" antibody="" by="" the="" lal="">
• Label
  Unconjugated

• Western Blot
  0.1 µg/mL
  Recombinant Mouse IL‑6 R alpha(Catalog # 1830-SR)
• Flow Cytometry
  2.5 µg/10⁶ cells
  Mouse CD3⁺ splenocytes
• Immunohistochemistry
  5-15 µg/mL
  See below
• CyTOF-ready
  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
• Mouse IL-6 R alphaSandwich Immunoassay
  Reagent
ELISA Capture (Matched Antibody Pair)
0.2-0.8 µg/mL 
Mouse IL‑6 R alphaAntibody (Catalog # AF1830)
ELISA Detection (Matched Antibody Pair)
0.1-0.4 µg/mL 
Mouse IL‑6 R alphaBiotinylated Antibody (Catalog # BAF1830)
ELISA Standard
 
Recombinant Mouse IL-6 R alpha (aa 20-357) Protein (Catalog # 1830-SR)
Neutralization
Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R. P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND₅₀) is typically 0.2-1 µg/mL in the presence of 0.25 ng/mL Recombinant Mouse IL‑6.

• Reconstitution
  Reconstitute at 0.2 mg/mL in sterile PBS.
• Shipping
  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
• Stability & Storage
  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

• References:
  1. Yamasaki, K. et al. (1988) Science 241:825.
  2. Sugita, T. et al. (1990) J. Exp. Med. 171:2001.
  3. Hibi, M. et al. (1990) Cell 63:1149.
  4. Saito, M. et al. (1992) J. Immunol. 148:4066.
  5. Novick, D. et al. (1989) J. Exp. Med. 170:1409.
  6. Jones, S.A. et al. (2001) FASEB J. 15:43.
  7. Jones, S.A. and S. Rose-John (2002) Biochim. Biophys. Acta 1592:251.
• Long Name:
  Interleukin 6 Receptor alpha
• Entrez Gene IDs:
  3570 (Human); 16194 (Mouse)
• Alternate Names:
  CD126; IL-6 R alpha; IL6R alpha; IL6R; IL-6Ra

Background:

Interleukin 6 (IL-6) is a multifunctional cytokine that exerts its activities by binding to a high-affinity receptor complex consisting of two membrane glycoproteins: an 80 kDa ligand binding subunit (IL-6 R alpha /CD126) and a 130 kDa nonligand-binding signal-transducing subunit (gp130/CD130) (1‑4). The mouse IL-6 R alphacDNA encodes a precursor type I transmembrane protein of 460 amino acids (aa) that contains a 19 aa signal sequence, a 345 aa extracellular ligand binding domain, a 21 aa transmembrane region, and a 75 aa cytoplasmic segment (2). The extracellular segment contains an Ig-like and a fibronectin-type III domain, plus a membrane proximal WSXWS motif. In their extracellular regions, mouse IL-6 R alphashares 89%, 51% and 50% aa identity with rat, human and porcine IL-6 R alpha, respectively. Unlike gp130 that is expressed ubiquitously, the cellular distribution of IL-6 R alphais predominantly limited to hepatocytes and leukocyte subpopulations such as monocytes, neutrophils, T and B cells. Soluble IL-6 R alphahas been found in various body fluids (5). Two soluble receptor isoforms that arise either from proteolytic cleavage of the membrane-bound IL-6 R alpha, or by alternative mRNA splicing (reported only in human) have been described (6, 7). Soluble IL-6 R alphabinds IL-6 with an affinity similar to that of the membrane-bound IL-6 R alpha. More importantly, the soluble IL-6 R alpha /IL-6 complex is capable of interacting with the membrane-bound gp130 to activate cells that lack an integral membrane IL-6 R alpha. It has been documented that elevated soluble IL-6 R is associated with numerous diseases including arthritic lesions, multiple myeloma and Crohn’s disease (6, 7).

      R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。